Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 7/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550356 | 0.82 | DRD3 (0.59) | HSD11B1DRD3NAMPTDRD2KDM4E | |
| SCHEMBL3052320 | 0.82 | HSD11B1 (0.55) | HSD11B1DRD3NAMPTDRD2KMT2A | |
| SCHEMBL3939911 | 0.81 | HSD11B1 (0.54) | HSD11B1DRD3NAMPTDRD2KMT2A | |
| SCHEMBL3216394 | 0.81 | HSD11B1 (0.54) | HSD11B1DRD3NAMPTDRD2KMT2A | |
| SCHEMBL12395531 | 0.79 | DRD3 (0.61) | HSD11B1DRD3NAMPTDRD2KMT2A | |
| SCHEMBL8149011 | 0.78 | HSD11B1 (0.47) | HSD11B1KMT2AKDM4ETDP1NPC1 | |
| SCHEMBL4893194 | 0.78 | HSD11B1 (0.47) | HSD11B1KMT2AKDM4ETDP1NPC1 | |
| SCHEMBL6057032 | 0.78 | — | — | |
| SCHEMBL16281565 | 0.78 | HSD11B1 (0.51) | HSD11B1DRD3NAMPTDRD2KMT2A | |
| SCHEMBL22281656 | 0.78 | HSD11B1 (0.51) | HSD11B1DRD3NAMPTDRD2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026336-B1 | 4-pyridinylimidazol-2-ylhydrocarbyl amine, (thio)urea, carbamic acid or sulfonamide derivatives, e.g., (2-(4-(4-Chloro-3-methoxy-phenyl)-5-pyridin-4-yl-1H-imidazol-2-yl)-2-methyl-propyl)-carbamic acid tert-butyl ester; Raf kinase inhibitors for the treatment of neurotraumatic diseases | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-04-11 | — | — | US | disclosed |
| EP-1232153-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-11-03 | — | — | EP | disclosed |
| EP-1232153-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001038324-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-31 | — | — | WO | disclosed |